Ozempic and Wegovy: same ingredients, very different licences

You searched this because something didn't add up

You've probably seen Ozempic everywhere, in newspaper headlines, social media posts, celebrity interviews. Then you noticed Wegovy and thought: hang on, aren't these the same thing? It's a fair question, and the confusion is genuinely understandable given how the two products are discussed in public. The short answer is yes, the active molecule is the same; the practical answer is that they are not interchangeable, and the distinction matters if you are trying to access treatment safely.

Semaglutide is the molecule. It works as a GLP-1 receptor agonist, it mimics a gut hormone that slows gastric emptying, reduces appetite and helps regulate blood sugar. Novo Nordisk developed it and holds UK marketing authorisations for both branded products. You can read more about the molecule itself on our semaglutide overview page, and about how Wegovy specifically works on our Wegovy guide.

The inactive ingredients (the excipients used to stabilise the injection solution) are also essentially the same across both pens. If you want the granular detail on those, our Wegovy inactive ingredients page sets them out from the summary of product characteristics.

Where the two products diverge: dose, indication and what a prescriber can legally do

The UK licence for Ozempic covers adults with type 2 diabetes. The doses approved for that indication are 0.25mg (starter), 0.5mg, 1mg, and 2mg. When you see Ozempic discussed in the context of weight loss, people are usually describing off-label use, a prescriber technically has discretion to prescribe off-label, but the MHRA is clear that GLP-1 medicines are not assessed or approved for quick or cosmetic weight loss, and responsible UK weight-loss services do not offer Ozempic for this purpose. The NHS medicines page on semaglutide explains the approved uses for each brand without ambiguity.

Wegovy's licence is specifically for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. Its dose ladder runs from 0.25mg up to a 2.4mg maintenance dose, with the option of a 7.2mg dose approved by the MHRA in April 2026 for adults with obesity. That higher dose was a meaningful development, trials reported around 20.7% average weight loss over 72 weeks, which starts to approach the results seen with tirzepatide. The main ingredient in Wegovy page covers these licensed specifics in more detail.

In practical terms: if someone offers you semaglutide for weight loss under the Ozempic brand, that is a red flag, not a deal. The correct product for weight management is Wegovy, prescribed after clinical assessment.

Ozempic is not available for weight loss through a regulated UK service, here is what is

At a UK-regulated weight-loss pharmacy, the two licensed injectable options are Wegovy (semaglutide) and Mounjaro (tirzepatide). Tirzepatide is a dual GIP and GLP-1 receptor agonist, which makes it the only medicine in its class currently licensed in the UK, a distinct mechanism from semaglutide. SURMOUNT-5, a head-to-head trial published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Both remain prescription-only, and a prescriber decides suitability based on your health history, not a self-assessment.

If you are curious about how the two licensed options compare on cost, our Wegovy cost page gives honest context on private pricing and what a transparent price should include. And if you are weighing up whether you might be a candidate for weight management treatment at all, our page on Wegovy for modest weight-loss goals covers the eligibility picture without sugar-coating it.

It is also worth knowing that oral semaglutide for weight management now exists: Wegovy tablets were approved by the MHRA on 11 June 2026, the first oral GLP-1 licensed for weight management in the UK. The tablet formulation uses the same semaglutide molecule with an absorption enhancer. That is not the same as Rybelsus, which is oral semaglutide for type 2 diabetes, a distinction worth understanding if you are exploring all your options on our weight-loss treatment overview.

The practical upshot: same molecule, different products, different rules

If a clinician, a headline or a seller implies that Ozempic and Wegovy are essentially the same thing and therefore one can substitute for the other, they are glossing over the part that actually governs what you can legally and safely be prescribed. The MHRA does not license medicines by molecule alone, it licenses specific products at specific doses for specific indications. That framework exists for good reason.

The question of whether the ingredients are the same is answered in one sentence: yes, the active ingredient is semaglutide in both. The fuller comparison of Wegovy and Ozempic on this site picks up every other dimension, dose, licence, availability, and what each product's approval history actually means for someone looking for weight management treatment in the UK today. Our Wegovy ingredients breakdown is also there if you want to go straight to the formulation detail.

Our clinical team reviews every consultation personally, a real prescriber, not automated software, reads your answers and makes a clinical decision. If you want to explore whether Wegovy or Mounjaro might be appropriate for you, the next step is straightforward.

Speak to our prescribers through a free consultation, no waiting list, same-day clinical review once you submit.